breast canceradjuvant chemotherapygranulocyte colony-stimulating factora combination of Taxoteredoxorubicinand cyclophosphanрак молочной железыадъювантная химиотерапиягранулоцитарный колониестимулирующий факторкомбинация Та- ксотера с доксорубицином и циклофосфаном1.1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:30— 942.Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:30— 942.2.2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the ran- domised trials. Lancet 2005;365:1687— 717.Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the ran- domised trials. Lancet 2005;365:1687— 717.3.3. Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin- based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24(36):5664—71.Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin- based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24(36):5664—71.4.4. Jones S., Holmes F., O'Shaughnessy J. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27(8):1177—83.Jones S., Holmes F., O'Shaughnessy J. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27(8):1177—83.5.5. Martin M., Pienkowski T., Mackey J. et al. Adjuvant docetaxel for node-posi- tive breast cancer. N Engl J Med 2005;352:2302—13.Martin M., Pienkowski T., Mackey J. et al. Adjuvant docetaxel for node-posi- tive breast cancer. N Engl J Med 2005;352:2302—13.6.6. Perez E. TAC - a new standard in adjuvant therapy for breast cancer? N Engl J Med 2005;352:2346—8.Perez E. TAC - a new standard in adjuvant therapy for breast cancer? N Engl J Med 2005;352:2346—8.7.7. Bonadonna G., Valagussa P., Moliterni A. et al. Adjuvant cyclophos- phamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow up. New Engl Med 1995;332:901—6.Bonadonna G., Valagussa P., Moliterni A. et al. Adjuvant cyclophos- phamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow up. New Engl Med 1995;332:901—6.8.8. Chirivella I., Bermejo B., Insa A. et al. Optimal delivery of anthracycline-based chemotherapy in adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2008;114(3):479—84.Chirivella I., Bermejo B., Insa A. et al. Optimal delivery of anthracycline-based chemotherapy in adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2008;114(3):479—84.9.9. Hryniuk W., Frei E., Wright F.A. et al. A single scale for comparing dose-inten- sity of all chemotherapy regimens in breast cancer: summation of dose intencity. J Clin Oncol 1998;16:3137—47.Hryniuk W., Frei E., Wright F.A. et al. A single scale for comparing dose-inten- sity of all chemotherapy regimens in breast cancer: summation of dose intencity. J Clin Oncol 1998;16:3137—47.10.10. Aapro M.S., Cameron D.A., Pettengel R. et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febril neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433—53.Aapro M.S., Cameron D.A., Pettengel R. et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febril neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433—53.11.11. Martin M., Lluch A., Segur M.A. et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte- colonystimulating factor to the TAC regi- men. Ann Oncol 2006;17(8):1205—112. Von Minckwitz G., Blohmer J., Loehr A. et al. Pegfilgastrim alone or with ciproflax- in significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadju- vant chemotherapy with docetaxel/dox- orubicin/cyclophosphamide (TAC). Eur J Cancer 2006;4(Suppl 2):151—2.Martin M., Lluch A., Segur M.A. et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte- colonystimulating factor to the TAC regi- men. Ann Oncol 2006;17(8):1205—112. Von Minckwitz G., Blohmer J., Loehr A. et al. Pegfilgastrim alone or with ciproflax- in significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadju- vant chemotherapy with docetaxel/dox- orubicin/cyclophosphamide (TAC). Eur J Cancer 2006;4(Suppl 2):151—2.